The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Overview of the clinical characteristics of adult patients with PICALM::MLLT10 fusion acute leukemia
Sankalp Arora, MD, MD Anderson Cancer Center, Houston, TX, discusses the clinical characteristics of adult patients with acute leukemia with the PICALM::MLLT10 fusion. In a retrospective study of 15 patients with this fusion, 14 presented with immature cells with mixed immunophenotype, 10 had extramedullary disease, and five had KRAS/NRAS mutations. This subgroup of patients had a poor prognosis, with an overall response rate (ORR) of around 50% when treated with classic induction regimens and a median overall survival (OS) of 19 months after a 32-month follow-up. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
